ClinicalTrials.gg
RecruitingNCT06638567GUIDEUpdated Jan 30, 2025

Postoperative Basal Bolus or Sliding Scale Insulin Regimen in DM2 and Its Effect on Surgical Site Infections.

An interventional study of Basal bolus insulin regimen in Diabetes Mellitus, Type 2 and Surgical Site Infection, sponsored by Abraham Hulst, MD, PhD. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-30.

Sponsored by Abraham Hulst, MD, PhD · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,008
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 326 studies in Diabetes Mellitus, Type 2 with a site in Netherlands — 28 open to participants now, 35 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Netherlands.

Planned enrollment
54th of 287
1,008 · median 134
Started
2025
with 6 others
No phase
99 of 326
14 open now
Primary completion
2027-02
later than 16 of 34 live
Registered
306th of 326
by date

Among the 326 studies in Diabetes Mellitus, Type 2 with a site in Netherlands, this one is the 54th largest by planned enrollment of the 287 interventional ones that give a count, is one of 7 that started in 2025, is one of 99 with no phase, reaches primary completion later than 16 of the 34 other live ones, and was the 306th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

28 of the 326 studies in Diabetes Mellitus, Type 2 with a site in Netherlands are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 326 studies in Diabetes Mellitus, Type 2 with a site in Netherlands, or all of them as a file.
02

Study summary

A multicentre, matched-pair, cluster randomised controlled superiority trial to investigate the effect of a proactive basal bolus insulin regimen compared to the reactive sliding scale insulin regimen, targeting a glucose level of 3.9-10.0 mmol/L, to reduce the number of surgical site infections within the first 30 days postoperatively in adult patients with diabetes mellitus type 2.

Read the detailed description

People with type 2 diabetes mellitus (PWT2D) are at increased risk of postoperative complications, especially surgical site infections (SSI).

The aim of this study to reduce SSI in PWT2D by implementing a proactive basal-bolus insulin regimen, compared to the reactive sliding scale regimen.

Adult patients with type 2 diabetes will be included in this multi-centre study.

Participants will receive a blind CGM, i.e. glucose data are masked for the participants and study team, from admission to the ward until discharge from the hospital. In addition, all participants are asked to complete several questionnaires 30 days after surgery.

Both regimens are currently used in clinical practice. Therefore, there is no additional trial-related burden depending on the intervention group allocation.

Participants will be monitored intensively and insulin dosage will be adjusted adequately to the measured glucose values by the treatment team.

The sample size is based on the SSI incidence rates. Wards are matched into pairs with comparable baseline incidence rates and in each pair, one ward will be randomly assigned to the intervention group; the other serves as the control. 18 wards from 8 participating centres are planned to be recruited, this translates to 9x2x56=1008 evaluable participants.

Keywords:

Diabetes mellitus, basal bolus, sliding scale, insulin regimen, surgical site infections

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Surgical Site Infection

Keywords

  • Diabetes Mellitus
  • Basal bolus regimen
  • Surgical site infections
  • Sliding scale
  • Insulin regimen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 or older
  • Diagnosed with type 2 diabetes mellitus
  • Undergoing gastointestinal or vascular surgery
  • Admitted to one of the participating surgical wards
  • Expected duration of stay at least one overnight stay
  • Willing and able to provide

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with type 1 diabetes mellitus
  • Female of who is pregnant or breastfeeding.
  • Undergoing complete pancreatectomy
  • Undergoing bariatric surgery
  • Patients using a continuous insulin pump at home
  • Patients undergoing a necrotectomy/wound debridement from a pre-existent wound.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,008 participants (estimated)

Study arms

  • Experimental
    Basal Bolus

    Patients daily dose of insulin is calculated by their treatment team: In insulin naive patients 0.4-0.5IU/kg and 0,3IU/kg for patients aged\>70 or patients with impaired kidney function with an estimated glucose filtration rate \<60ml/min and 80-100% of own insulin for insulin-users. They receive half of this daily dose in long-acting insulin once a day. The other half of their total daily dose of insulin is provided as short-acting mealtime insulin. This short-acting insulin is administered before each meal. When needed, extra insulin can be given when needed. The measurements of blood glucose values are before each meal and at bedtime (4x/day).

    Other: Basal bolus insulin regimen

  • No intervention
    Sliding Scale

    Short-acting insulin is administered when blood glucose value is above 10,0 mmol/L according to a standardized dosage schedule. The measurements of blood glucose values are before each meal and at bedtime (4x/day).

Interventions

  • OtherBasal bolus insulin regimen

    Combination of long-acting and short-acting insulin in a proactive schedule for achieving better blood glucose values postoperatively

06

What researchers measure

Primary outcomes

  1. Surgical site infection

    Incidence of postoperative surgical site infection, according to the criteria of the centres of disease control (CDC) for superficial incisional SSI, deep incisional SSI and organ / space SSI. SSIs will be measured at 30 days postoperatively via BLUEBELLE questionnaire, diagnosis by surgeon during standard postoperative visit at the surgery clinic 3-5 weeks after surgery and chart review.

    Time frame: Until 30 days after surgery

Secondary outcomes

  1. Postoperative hospital-acquired infections (non-SSI)

    Incidence of hospital-acquired infections, other than surgical site infections

    Time frame: Recorded at 30 days postoperatively

  2. Length of stay in the hospital (LoS-Hos)

    Length of stay in the hospital, measured in days from admission to discharge from the hospital.

    Time frame: Recorded at 30 days postoperatively

  3. Hospital readmission

    Rate of hospital readmissions within 30 days after surgery

    Time frame: Recorded 30 days postoperatively

  4. Days at home (DAH30)

    Patient-reported number of days at home after surgery, between 0 and 30.

    Time frame: Recorded 30 days postoperatively

  5. Postoperative disability

    Patient-reported level of disability 30 days after surgery, using the WHODAS-2.0 questionnaire. Summarized in a score between 0-100.

    Time frame: Recorded 30 days postoperatively

  6. Quality of life (QoL) after surgery

    Patient-reported health-related quality of life 30 days after surgery, using the EuroQol 5D5L questionnaire, summarized in a score between 0 and 1.

    Time frame: Recorded 30 days postoperatively

  7. Glucose 2

    Incidence of grade 2 hypoglycemia, a blood glucose below 3.0mmol/L.

    Time frame: Measured 4 times a day, until discharge from the hospital, up to 30 days.

  8. Glucose 3

    Incidence of grade 1 hyperglycemia, a blood glucose above 10.0mmol/L.

    Time frame: Measured 4 times a day, until discharge from the hospital, up to 30 days.

  9. Glucose 4

    Incidence of grade 2 hyperglycemia, a blood glucose above 14.0mmol/L.

    Time frame: Measured 4 times a day, until discharge from the hospital, up to 30 days.

  10. CGM1

    Percentage of time within glycaemic target range (3.9-10.0 mmol/L) per day and over hospital admission. This is measured with the continuous glucose monitor (CGM).

    Time frame: Measured with a 5-minute interval, until discharge from the hospital, up to 30 days.

  11. CGM2

    Percentage of time below glycaemic target range (\<3.9mmol/L) per day and over hospital admission. This is measured with the continuous glucose monitor (CGM).

    Time frame: Measured with a 5-minute interval, until discharge from the hospital, up to 30 days.

  12. CGM3

    Percentage of time above glycaemic target range (\>10.0mmol/L) per day and over hospital admission. This is measured with the continuous glucose monitor (CGM).

    Time frame: Measured with a 5-minute interval, until discharge from the hospital, up to 30 days.

  13. Cost-effectiveness 1

    The cost-effectiveness of the basal bolus insulin regimen compared to the sliding scale regimen, considering the costs per prevented of SSI in a cost-effectiveness analysis.

    Time frame: Until 30 days after surgery

  14. Cost-effectiveness 2

    The number of quality adjusted life years (QALYs) gained after a cost-utility analysis.

    Time frame: Up to 30 days after surgery.

  15. Protocol adherence

    The adherence to the protocol until discharge from the hospital

    Time frame: During the hospital stay, until discharge

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kao LS, Phatak UR. Glycemic control and prevention of surgical site infection. Surg Infect (Larchmt). 2013 Oct;14(5):437-44. doi: 10.1089/sur.2013.008. Epub 2013 Oct 10. PubMed 24111757 ↗
  • Kotagal M, Symons RG, Hirsch IB, Umpierrez GE, Dellinger EP, Farrokhi ET, Flum DR; SCOAP-CERTAIN Collaborative. Perioperative hyperglycemia and risk of adverse events among patients with and without diabetes. Ann Surg. 2015 Jan;261(1):97-103. doi: 10.1097/SLA.0000000000000688. PubMed 25133932 ↗
  • Polderman JA, Van Velzen L, Wasmoeth LG, Eshuis JH, Houweling PL, Hollmann MW, Devries JH, Preckel B, Hermanides J. Hyperglycemia and ambulatory surgery. Minerva Anestesiol. 2015 Sep;81(9):951-9. Epub 2015 Jan 16. PubMed 25592489 ↗
  • de Vries FE, Gans SL, Solomkin JS, Allegranzi B, Egger M, Dellinger EP, Boermeester MA. Meta-analysis of lower perioperative blood glucose target levels for reduction of surgical-site infection. Br J Surg. 2017 Jan;104(2):e95-e105. doi: 10.1002/bjs.10424. Epub 2016 Nov 30. PubMed 27901264 ↗
  • Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, Umpierrez D, Newton C, Olson D, Rizzo M. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011 Feb;34(2):256-61. doi: 10.2337/dc10-1407. Epub 2011 Jan 12. PubMed 21228246 ↗
  • de Lissovoy G, Fraeman K, Hutchins V, Murphy D, Song D, Vaughn BB. Surgical site infection: incidence and impact on hospital utilization and treatment costs. Am J Infect Control. 2009 Jun;37(5):387-397. doi: 10.1016/j.ajic.2008.12.010. Epub 2009 Apr 23. PubMed 19398246 ↗
  • Phillips VL, Byrd AL, Adeel S, Peng L, Smiley DD, Umpierrez GE. A Comparison of Inpatient Cost Per Day in General Surgery Patients with Type 2 Diabetes Treated with Basal-Bolus versus Sliding Scale Insulin Regimens. Pharmacoecon Open. 2017;1(2):109-115. doi: 10.1007/s41669-017-0020-9. Epub 2017 Apr 21. PubMed 28660256 ↗
  • Koek MBG, van der Kooi TII, Stigter FCA, de Boer PT, de Gier B, Hopmans TEM, de Greeff SC; Burden of SSI Study Group. Burden of surgical site infections in the Netherlands: cost analyses and disability-adjusted life years. J Hosp Infect. 2019 Nov;103(3):293-302. doi: 10.1016/j.jhin.2019.07.010. Epub 2019 Jul 19. PubMed 31330166 ↗
  • Fowler AJ, Wahedally MAH, Abbott TEF, Smuk M, Prowle JR, Pearse RM, Cromwell DA. Death after surgery among patients with chronic disease: prospective study of routinely collected data in the English NHS. Br J Anaesth. 2022 Feb;128(2):333-342. doi: 10.1016/j.bja.2021.11.011. Epub 2021 Dec 20. PubMed 34949439 ↗
  • Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet. 2009 May 23;373(9677):1798-807. doi: 10.1016/S0140-6736(09)60553-5. PubMed 19465235 ↗
  • Lai J, Li Q, He Y, Zou S, Bai X, Rastogi S. Glycemic Control Regimens in the Prevention of Surgical Site Infections: A Meta-Analysis of Randomized Clinical Trials. Front Surg. 2022 Mar 25;9:855409. doi: 10.3389/fsurg.2022.855409. eCollection 2022. Erratum In: Front Surg. 2022 Jun 17;9:912295. doi: 10.3389/fsurg.2022.912295. PubMed 35402490 ↗
  • Colunga-Lozano LE, Gonzalez Torres FJ, Delgado-Figueroa N, Gonzalez-Padilla DA, Hernandez AV, Roman Y, Cuello-Garcia CA. Sliding scale insulin for non-critically ill hospitalised adults with diabetes mellitus. Cochrane Database Syst Rev. 2018 Nov 29;11(11):CD011296. doi: 10.1002/14651858.CD011296.pub2. PubMed 30488948 ↗
  • Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Tokumaru T, Iiyama T, Sugimoto T, Kobayashi M, Yokoyama M, Hanazaki K. Intensive versus intermediate glucose control in surgical intensive care unit patients. Diabetes Care. 2014 Jun;37(6):1516-24. doi: 10.2337/dc13-1771. Epub 2014 Mar 12. PubMed 24623024 ↗
  • Yuan J, Liu T, Zhang X, Si Y, Ye Y, Zhao C, Wang Q, Shen X. Intensive Versus Conventional Glycemic Control in Patients with Diabetes During Enteral Nutrition After Gastrectomy. J Gastrointest Surg. 2015 Aug;19(8):1553-8. doi: 10.1007/s11605-015-2871-7. Epub 2015 Jun 18. PubMed 26084869 ↗
  • Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, Puig A, Mejia R. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007 Sep;30(9):2181-6. doi: 10.2337/dc07-0295. Epub 2007 May 18. PubMed 17513708 ↗
  • Migdal AL, Fortin-Leung C, Pasquel F, Wang H, Peng L, Umpierrez GE. Inpatient Glycemic Control With Sliding Scale Insulin in Noncritical Patients With Type 2 Diabetes: Who Can Slide? J Hosp Med. 2021 Aug;16(8):462-468. doi: 10.12788/jhm.3654. PubMed 34328842 ↗
  • Korytkowski MT, Muniyappa R, Antinori-Lent K, Donihi AC, Drincic AT, Hirsch IB, Luger A, McDonnell ME, Murad MH, Nielsen C, Pegg C, Rushakoff RJ, Santesso N, Umpierrez GE. Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2022 Jul 14;107(8):2101-2128. doi: 10.1210/clinem/dgac278. PubMed 35690958 ↗

Individual participant data

Plan to share: Yes — Complete data collection methods and results will be shared with other researchers upon a formal request made to the principal investigator including a detailed motivation for the request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: One year after reviewed publication of the primary results

Access criteria: Official request to the principal investigator

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Feb 2027, 25 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 25 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2024
First posted
Oct 15, 2024
StartActual
Jan 3, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Sep 2027
Last update
Jan 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06638567
Lead sponsor
Abraham Hulst, MD, PhD
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
Responsible party
Abraham Hulst, MD, PhD (Clinical investigator, anesthesiologist, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Sponsor-investigator
First posted
Oct 15, 2024
Start date
Jan 3, 2025
Primary completion
Feb 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jan 30, 2025

Study contacts

Ayla Y. Stobbe, MD
Contact
a.y.stobbe@amsterdamumc.nl
0031205669111
Sarah E. Siegelaar, MD, PhD
Contact
s.e.siegelaar@amsterdamumc.nl
0031205669111
Sarah E. Siegelaar, MD, PhD
principal investigator · Amsterdam UMC, location AMC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion